Cue Biopharma, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cue Biopharma, Inc.
Cue Biopharma Brings Autoimmune Back To The Fore With Ono Deal
Deal Snapshot: Cue’s pipeline is heavy on oncology, but it partnered with Merck on autoimmune in 2017 and while that work has shifted to cancer, the Ono partnership puts the focus back on autoimmune disease.
Scrip Asks…What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances
Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.
Tech Transfer Roundup: Inside The Law That Transformed The Research Landscape
The Bayh-Dole act of 1980 facilitated deal-making between private-sector firms and research institutions, largely seeding the US biotech industry. Plus, an overview of the latest tech transfer deals.
NIH, BARDA Seek Out New Point-Of-Care Diagnostics For RADx Program To Boost US COVID-19 Testing
The US National Institutes of Health and the Biomedical Advanced Research and Development Authority are asking manufacturers to provide new COVID-19 diagnostic candidates for NIH’s Rapid Acceleration of Diagnostics (RADx) program.
- Large Molecule
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.